GLP-1 Telehealth Informed Consent Explained: What You’re Agreeing To Before You Sign
Last verified: May 16, 2026. Next scheduled review: June 2026 for FDA updates; August 2026 for full provider and state-policy refresh.
This page is educational. It is not medical or legal advice.
GLP-1 telehealth informed consent is the agreement an online weight-loss clinic asks you to read and accept before any prescription is written. A strong one explains nine things in plain English: who is treating you, where they’re licensed, what medication you’ll get, whether that medication is FDA-approved or compounded, the medication’s real risks, what telehealth can’t do, who sees your private health information, what counts as an emergency, and your right to walk away at any time. If your consent form is missing two or three of those, that’s not paperwork. That’s a signal to pause.
Below is the same decoder we use when we audit GLP-1 telehealth providers: the nine elements, what each one should actually say, what major providers’ consent forms include today (we checked five), and the seven red flags that should make you stop and ask before you click.
Quick answer: what a strong GLP-1 telehealth consent covers
| What a strong consent answers | Why it matters |
|---|---|
| Who is the clinician, and are they licensed in your state? | Telehealth care is governed by the law of the state you're in, not the state the company is based in. |
| Is the medication FDA-approved or compounded? | The FDA says compounded GLP-1s are not FDA-approved and not FDA-approved generics of Ozempic, Wegovy, Mounjaro, or Zepbound. |
| What are the medication's real risks and hard stops? | GLP-1 labels list thyroid cancer warnings, pancreatitis, gallbladder disease, pregnancy warnings, anesthesia risk, and more. |
| What can a video or messaging visit actually evaluate? | No physical exam. Often no in-person labs. Vitals may be self-reported. |
| What symptoms mean you should contact the prescriber, urgent care, the ER, or 911? | Trouble breathing, facial or throat swelling, fainting, severe persistent abdominal pain, persistent vomiting, dehydration symptoms, or vision changes are not "side effects to ride out." |
| How do you reach a real person after you start? | A medication that's adjusted every few weeks needs a real follow-up path, not a help-desk ticket. |
| What will it cost — today, at refill, and after dose increases? | Billing terms aren't medical consent, but hidden cost terms change the decision. |
If your provider’s form doesn’t clearly answer all seven, keep reading. You’re not being paranoid. You’re being responsible.
What does “GLP-1 telehealth informed consent” actually mean?
Informed consent is the back-and-forth process where a licensed clinician makes sure you understand what’s about to happen to you — the benefits, the real risks, the alternatives, and your right to say no — before treatment begins. The form is the receipt for that conversation. It is not the conversation itself.
State medical boards, the Federation of State Medical Boards (FSMB), and the American Medical Association all say the same thing: telehealth must meet the same standard of care as an in-person visit (FSMB Model Policy, 2022). A checkbox at the end of a fast intake is the record. It is not, by itself, consent.
The three kinds of “consent” you’ll be asked for (only one is actually informed consent)
Most GLP-1 platforms bundle three different agreements into the same checkout flow. They get treated like one decision. They aren’t.
| Type of consent | What it covers | What it doesn’t cover |
|---|---|---|
| Telehealth consent | Remote care has limits — no physical exam, possible tech failure, no in-person evaluation. Plus your right to refuse telehealth and ask for in-person care instead. | Whether the medication is right for you. |
| Medication informed consent | The benefits and risks of the specific GLP-1 you may be prescribed, whether it's FDA-approved or compounded, contraindications, alternatives, and the follow-up plan. | Subscription billing or refund rules. |
| Financial consent | Subscription charges, refill timing, cancellation rules, and refund windows. Often includes an arbitration clause with an opt-out window. | Anything medical. |
Why this is a 2026 question, not a 2022 question
The regulatory timeline that changed what a defensible consent must say:
| Date | Event |
|---|---|
| Oct. 2, 2024 | FDA initially announced tirzepatide shortage resolved. |
| Dec. 19, 2024 | After reevaluation, FDA confirmed tirzepatide shortage resolved. |
| Feb. 18, 2025 | 503A pharmacy enforcement-discretion window for tirzepatide ended. |
| Feb. 21, 2025 | FDA announced semaglutide shortage resolved. |
| Mar. 19, 2025 | 503B outsourcing facility enforcement-discretion window for tirzepatide ended. |
| Apr. 22, 2025 | 503A pharmacy enforcement-discretion window for semaglutide ended. |
| May 22, 2025 | 503B outsourcing facility enforcement-discretion window for semaglutide ended. |
| Mar. 3, 2026 | FDA announced 30 warning letters to telehealth companies over illegal marketing of compounded GLP-1s. |
| Apr. 30 / May 1, 2026 | FDA and the Federal Register proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Public comment deadline: June 30, 2026. |
Sources: FDA, "FDA Clarifies Policies for Compounders," April 2026; FDA, "FDA Warns 30 Telehealth Companies," March 3, 2026; 91 Fed. Reg. 23431 (May 1, 2026).
The 9 things your GLP-1 telehealth consent should disclose before you sign
Built from FSMB Model Policy on telemedicine, AMA Code of Medical Ethics §1.1.5, current FDA prescribing information for the GLP-1 drug class, HHS Telehealth.gov guidance, and state telehealth statutes via CCHP. Missing three or more elements is a pause-and-ask signal.
Who is treating you, and where are they licensed?
Strong
Names the prescribing clinician or supervising physician, lists their license type (MD, DO, NP, PA), and tells you which state license they hold. Gives you a way to reach them directly.
Weak
"Our medical group will review your information." No name. No license number. The clinician is assigned after you pay.
Why it matters: In most states, an online clinician must be licensed in the state where you are physically located when you receive care — not where the company is based. If something goes wrong, you need to know which state's medical board oversees the person who prescribed to you.
Your right to refuse telehealth and ask for in-person care
Strong
A clear, separate clause that says you can decline telehealth and request in-person care, and that doing so will not affect your future right to care.
Weak
Buried inside a "limitations of telehealth" paragraph, or absent.
Why it matters: Telehealth consent rules vary by state. Even where this clause isn't legally mandatory, it's a strong consent element because it tells the patient telehealth is voluntary and in-person care remains an option.
What telehealth can't do
Strong
Specific list of what cannot be evaluated remotely — no physical exam, possible technology or connection failure, self-reported vitals, no in-person labs unless ordered separately, no direct visualization of your injection site.
Weak
A single sentence saying telehealth has "limitations" with no specifics.
Why it matters: Remote care cannot palpate your abdomen or thyroid, directly assess hydration, examine an injection site in person, or perform same-visit labs. A real consent names those limits so you can decide whether they're acceptable for your situation.
The medication itself — what it is, what it does, what's in the syringe (or tablet)
Strong
Names the specific drug (semaglutide, tirzepatide, liraglutide, orforglipron), the brand name if applicable, the route, dosage form, schedule, starting dose, and the planned titration schedule.
Weak
"You may receive a GLP-1 medication." No name. No dose. No titration schedule. Pharmacy unnamed until after you pay.
Why it matters: You should know the name of the drug before you agree to take it. That's the floor.
FDA-approved or compounded — the disclosure that matters most in 2026
Strong
A clear, plain-English statement saying whether the product is FDA-approved (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Rybelsus) or compounded (custom-prepared by a state-licensed pharmacy, not FDA-approved, not reviewed by FDA for safety or efficacy, and not an FDA-approved generic of any FDA-approved drug).
Weak
"Our pharmacy is FDA-regulated" (true of every U.S. pharmacy — tells you nothing about the drug). "Contains the same active ingredient as Ozempic" (FDA has specifically flagged this language in warning letters). No statement of approval status at all.
Why it matters: This is the single most important disclosure on the page. The FDA has been most active about enforcing it.
The actual medical risks — named, not waved at
Strong
Lists the boxed warnings and major contraindications from the medication's FDA label: thyroid C-cell tumor risk, medullary thyroid carcinoma (MTC) or MEN 2 contraindication, pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, hypoglycemia, diabetic retinopathy, hypersensitivity, pregnancy and breastfeeding warnings, anesthesia/surgery aspiration risk, and oral contraceptive interaction.
Weak
"Common side effects may include nausea and vomiting." That's the bare minimum — not the risk profile a patient needs to consent.
Why it matters: From DailyMed labels for Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus.
Privacy, HIPAA, and who else sees your data
Strong
Names the parties who will see your protected health information (PHI): the prescribing clinician, the fulfilling pharmacy, your insurance if applicable, any specific third-party services (labs vendor). Asks for separate written authorization for any non-treatment use, like marketing or third-party app sharing.
Weak
A catch-all "we may share your information with partners" with no list of who those partners are.
Why it matters: HIPAA protects PHI. But the authorization to share it for non-treatment purposes is a separate decision.
Emergencies — what's not covered and what to do instead
Strong
A clear, prominent statement that telehealth is not for emergencies, with specific examples of symptoms that mean you should contact the prescriber, go to urgent care, go to the ER, or call 911. Examples: trouble breathing, facial or throat swelling, fainting, severe persistent abdominal pain (possible sign of pancreatitis or gallbladder attack), persistent vomiting that prevents keeping fluids down, signs of severe dehydration, or vision changes.
Weak
A single buried sentence: "Not for emergencies. Call 911."
Why it matters: Vague emergency instructions can lead to dangerous delays in seeking care.
Your right to withdraw consent and stop at any time
Strong
Tells you how to withdraw consent — who to contact, what happens to any ongoing prescriptions, and that withdrawal will not be punished by any care-related penalty beyond standard subscription terms.
Weak
Withdrawal is tied to the refund and cancellation process, or absent. You can't tell whether stopping the medication is medically supported or just financially permitted.
Why it matters: You can stop. That right should be clearly and separately stated.
Compounded vs. FDA-approved GLP-1: the single most important sentence in your consent
If you read nothing else, read this section. This is where most patients are confused and where the FDA has been actively writing warning letters.
FDA-approved GLP-1
Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Rybelsus — reviewed by the FDA for safety, manufacturing quality, and effectiveness for specific medical uses at specific doses. Comes in the manufacturer’s FDA-approved dosage form and labeling.
Compounded GLP-1
Custom-mixed by a state-licensed compounding pharmacy. The finished product has not been reviewed by the FDA for safety, effectiveness, or quality before it’s shipped. Not an FDA-approved generic — no FDA-approved generics of semaglutide or tirzepatide exist as of May 2026.
The FDA has also warned specifically about semaglutide salt forms (different chemical forms of the active ingredient not evaluated for safety), fraudulent compounded GLP-1 labels, dosing errors with compounded injectables, products arriving warm or under-refrigerated, and products sold as “research peptides” or “not for human consumption.” This is a regulatory category difference, not a marketing one.
Language that should make you stop scrolling
These phrases have all appeared in FDA warning letters or NAD actions in 2024–2026:
| Phrase | Why it’s a problem |
|---|---|
| "Generic Ozempic" or "generic Wegovy" | No FDA-approved generic exists. The phrase is misleading by FDA's standard. |
| "Same as" or "equivalent to" Wegovy/Zepbound | FDA warning letters have specifically targeted this language. Compounded products have not been shown to be equivalent. |
| "FDA-regulated facility" used to imply the drug is FDA-approved | The pharmacy may be regulated. The drug isn't approved. Don't conflate the two. |
| "Our proprietary GLP-1 formula" | The product should be a named, identifiable drug. "Proprietary blend" is supplement language, not prescription-drug language. |
| "No prescription needed" | GLP-1 medications are prescription drugs. Period. |
| "Research peptide" or "not for human consumption" | That's a chemistry-supplier disclaimer, not a patient prescription path. Walk away. |
| Pharmacy name only revealed after you pay | You should be able to look up the pharmacy before consenting to use it. |
Copy this question into your provider’s support chat:
“Can you confirm in writing whether the medication you’d prescribe is FDA-approved or compounded, and if compounded, the pharmacy name and whether it is a 503A pharmacy or 503B outsourcing facility?”
A real program will answer in plain language. A program that gives you marketing-speak in response is telling you what you need to know.
How to verify the pharmacy before you consent
- Ask for the pharmacy name before payment. A serious program will tell you. A program that won’t tell you is a flag.
- Confirm the pharmacy is licensed. State boards of pharmacy maintain public license lookups. For online pharmacy safety, the FDA’s BeSafeRx resources are a starting point.
- Check the label when it arrives. Look for the pharmacy name, address, lot number, expiration date, concentration, and clear dose instructions. Spelling errors, missing required fields, or a different pharmacy name than disclosed are all problems.
- Refuse and contact the pharmacy if the shipment arrives warm. The FDA has specifically warned against using injectable GLP-1 medication that arrives warm or with insufficient refrigeration. Do not inject it. Contact the pharmacy and the prescriber.
- If something looks wrong, stop. A wrong concentration, a wrong drug name, or a mismatched pharmacy address is a reason to pause before the first dose.
The specific GLP-1 risks your consent must name
A consent that says “common side effects include nausea, vomiting, and diarrhea” is not a real risk disclosure. It’s the bottom of an FDA label, pulled out without the parts that decide whether you should take the medication at all.
| Risk area | What the consent should say | The question to ask if it doesn’t |
|---|---|---|
| Thyroid C-cell tumors / MTC / MEN 2 | GLP-1 labels carry a boxed warning for thyroid C-cell tumor risk in animal studies. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication — meaning you should not take the medication. | "Did my intake screen for personal or family history of MTC or MEN 2 specifically?" |
| Serious allergy | Prior serious allergic reaction to a GLP-1 is a contraindication. | "What symptoms mean I should stop the medication and seek emergency care?" |
| Pancreatitis | Severe, persistent abdominal pain (often radiating to the back) can signal pancreatitis. The label tells patients to stop the drug and contact a provider. | "What do I do if I develop severe stomach pain?" |
| Gallbladder disease | GLP-1s have been associated with gallbladder problems, including gallstones, especially with rapid weight loss. | "Does my history of gallstones change the plan?" |
| Kidney injury | Severe vomiting or diarrhea can lead to dehydration and acute kidney injury. | "When should I call if I can't keep fluids down?" |
| Severe GI disease / gastroparesis | GLP-1s slow stomach emptying and can worsen certain GI conditions. | "Does my GI history make remote-only prescribing inappropriate?" |
| Hypoglycemia (low blood sugar) | Risk rises sharply if you're also taking insulin or a sulfonylurea for diabetes. | "Do any of my current medications need dose adjustment when I start?" |
| Diabetic retinopathy | Semaglutide labels list a risk of retinopathy complications in patients with type 2 diabetes. | "If I have diabetic eye disease, should my eye doctor be involved?" |
| Surgery and anesthesia | GLP-1 labels discuss pulmonary aspiration risk during general anesthesia or deep sedation, because GLP-1s slow stomach emptying. | "What should I tell my surgeon or anesthesiologist before any procedure?" |
| Pregnancy and breastfeeding | The Wegovy Medication Guide instructs patients to stop Wegovy at least 2 months before a planned pregnancy because of the long half-life of semaglutide. | "If I'm trying to conceive or might become pregnant, what's the plan?" |
| Oral hormonal contraceptives | The Zepbound label explains that tirzepatide can reduce the effectiveness of oral contraceptives. Patients are advised to switch to a non-oral contraceptive or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. | "If I'm on the pill, what backup contraception do I need and for how long?" |
Sources: Wegovy and Zepbound prescribing information and Medication Guides, DailyMed. Verify label revision dates before relying on any cited fact.
The pregnancy and oral-contraceptive details are two of the most consequential pieces of information on those labels, and they are missing from a striking number of online consent forms. If you’re prescribed tirzepatide on Monday and your consent doesn’t mention the contraceptive interaction, that’s not a small omission. See our full guide on GLP-1 and oral contraceptives.
What telehealth genuinely can’t do — and why your consent should say so
A real telehealth consent doesn’t pretend that a video call is the same as an in-person visit. It tells you exactly what’s missing so you can decide whether that’s okay for your situation.
A remote GLP-1 visit usually cannot:
- Perform a physical exam — palpate your abdomen, check your thyroid, listen to your lungs, look at your injection site, or assess your hydration in person.
- Take your vitals directly. Weight, height, and blood pressure are usually self-reported.
- Run in-person labs in the same visit. Labs may be requested separately, ordered to a local draw site, or based on existing records.
- See or hear non-verbal cues a real exam might catch.
- Cover every state. Some platforms can’t legally prescribe to patients in certain states.
Weak consent says:
“Telehealth has limitations.”
Strong consent says:
“Telehealth cannot replace an in-person physical examination. Your clinician may recommend in-person labs, in-person evaluation, urgent care, or emergency care if your symptoms or history require it. By accepting telehealth services, you understand these limitations.”
Can a GLP-1 be prescribed after only an online questionnaire?
Sometimes — but the consent form should tell you how care is delivered before you agree. A useful consent will say whether the model is asynchronous (you submit information; a clinician reviews it later without a live conversation), synchronous video, synchronous phone, or messaging-based.
The legal acceptability of online-questionnaire-only prescribing depends on:
- The patient’s state (HHS notes telehealth rules vary by state; CCHP tracks the variation).
- The provider’s license (the clinician must be licensed in the state where the patient is physically located when care is provided).
- The standard of care for the specific condition.
- The medical facts of the intake — a complex case with multiple risk factors may not be appropriately handled by questionnaire alone.
Sources: HHS Telehealth.gov, "Obtaining Informed Consent"; CCHP State Telehealth Policy Tracker.
Pregnancy, birth control, and surgery — three details most consent forms miss
Pregnancy
Both semaglutide and tirzepatide have long half-lives — they stay in your body for weeks after the last dose. The Wegovy Medication Guide tells patients to stop Wegovy at least 2 months before a planned pregnancy. If your consent form doesn’t mention this and you’re a woman of reproductive age, ask. Ask before your first dose.
Oral contraceptives and tirzepatide
Tirzepatide slows stomach emptying, which can reduce how well your oral contraceptive (the pill) is absorbed. The Zepbound label tells patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. If your consent form doesn’t say this and you’re on the pill, that’s an actionable gap. Ask before your first dose.
Full guide: GLP-1 and Oral Contraceptives: Which Birth Control Pills Need Backup?
Surgery and anesthesia
GLP-1s slow stomach emptying. That means your stomach may not be empty when an anesthesiologist expects it to be, raising the risk of pulmonary aspiration during general anesthesia. The current multi-society guidance (AGA, ASA, and partner organizations) is that most patients can continue GLP-1 drugs before elective procedures, while higher-risk patients may need a 24-hour liquid diet, anesthesia-plan adjustments, or a delay. The non-negotiable part: tell your surgeon and anesthesiologist about GLP-1 use well before any planned procedure.
These three aren’t fine print. They are the kinds of disclosures that decide whether a medication is safe for the next year of your life.
State rules: what your state actually requires
State law sets the floor for telehealth consent. Some states require written consent. Some accept verbal. Some require a separate weight-loss consumer disclosure on top. Verify your specific state’s current rule before relying on it. CCHP refreshes its tracker quarterly.
| State | Written consent required? | Verbal acceptable? | Documentation required? | Notable additional rules |
|---|---|---|---|---|
| Alaska | Either form acceptable | Yes | Yes | AK Admin Code Title 12, 60.415 |
| California | Either form acceptable | Yes | Yes | Telehealth Advancement Act (Bus. & Prof. Code §2290.5) — provider must inform the patient, obtain verbal or written consent before the visit, and document it |
| Florida | Written required for obesity-drug prescribing | — | Yes | Florida Weight-Loss Consumer Bill of Rights (Fla. Stat. §501.0575) + Fla. Admin. Code 64B8-9.012 (BMI documentation, reevaluation at least once every 3 months, written informed consent for obesity drugs) |
| Idaho | Required (written required for Medicaid) | — | Yes | — |
| Louisiana | Verbal and/or written | Yes | Yes | LA Admin. Code LAC 46, Part LX, Sec. 505 |
| Mississippi | Required | — | Yes | Aug. 2023 semaglutide guidance, supplemented Aug. 6, 2024. The 2024 supplement allows certain compounded GLP-1/GIP medications under a limited exemption with documented clinical need, verified API source, and certificate-of-analysis. Nonqualifying compounding remains restricted. |
| New York | Documentation required; written not required for NYS Medicaid telehealth | — | Yes | Informed consent must be documented in the chart before or during the first telehealth visit. |
| Texas | Either form acceptable | Yes | Yes | Medicaid requires signed and dated consent |
| Utah | No specific telehealth consent guideline | — | — | General medical-consent rules still apply |
| Vermont | Either form acceptable | Yes | Yes | — |
Florida is special
Fla. Stat. §501.0575 — Florida Weight-Loss Consumer Bill of Rights: required for every weight-loss program, including telehealth GLP-1 programs. A separate document from medical informed consent.
Fla. Admin. Code 64B8-9.012 — requires written informed consent for any obesity-drug prescription, documented BMI criteria, and reevaluation at least every 3 months for patients on ongoing obesity-drug therapy.
California’s specific rule
California’s Telehealth Advancement Act (Bus. & Prof. Code §2290.5) requires the provider to inform the patient about the use of telehealth, obtain verbal or written consent before the telehealth visit, and document the consent. If you’re a California resident and the consent never asked for an acknowledgment or a written click-through, the provider may not be meeting state requirements.
How to verify your state in 4 steps
- Check the CCHP Policy Finder for your state at cchpca.org.
- Check your state medical board’s current telehealth and prescribing rules.
- Ask the provider in writing which state license applies to your visit and how they meet your state’s consent requirement.
- Save the consent and the provider’s response before you take the first dose.
How major GLP-1 telehealth providers’ consent forms compare — our 2026 audit
We pulled publicly posted consent pages from five GLP-1 telehealth providers and rated each one against the nine-element framework. This is a disclosure audit, not a legal compliance score. Verification date: May 16, 2026. Re-verify before relying on any specific cell for an enrollment decision.
| Provider | 1. Clinician identity | 2. Right to refuse | 3. Telehealth limits | 4. Medication named | 5. FDA-approved vs compounded | 6. Risks named | 7. Privacy & data | 8. Emergency limits | 9. Right to withdraw |
|---|---|---|---|---|---|---|---|---|---|
| Ivim Health | ⚠ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gala GLP-1 | ⚠ | ✓ | ✓ | ⚠ | ⚠ | ⚠ | ✓ | ✓ | ✓ |
| Hers (FL weight-loss consent only) | ⚠ | ⚠ | ⚠ | ⚠ | ⚠ | ✓ | ⚠ | ⚠ | ⚠ |
| CoraDoc | ⚠ | ⚠ | ✓ | ✓ | ⚠ | ⚠ | ✓ | ✓ | ✓ |
| Dr. B | ⚠ | ✓ | ✓ | ⚠ | ⚠ | ✓ | ✓ | ✓ | ✓ |
Note on the Hers row
The publicly visible Hers Florida consent URL is a Florida-specific weight-loss-treatment consent. It is not the full telehealth or GLP-1 medication consent that a Hers patient signs during enrollment. The fuller Hers enrollment flow may include additional disclosures not visible at that URL.
What the audit shows
- Element 3 (telehealth limits) is the most consistent — every form covers it at least partially. It’s the most boilerplate part.
- Element 5 (FDA-approved vs compounded) is the weakest column. Several pages mention compounding but bury the regulatory category in legal phrasing patients won’t parse. Given that this is the disclosure the FDA has been most active about, it’s the one most likely to tighten next.
- Element 1 (clinician identity) is almost universally vague. Most consent forms reference “your provider” or “our medical group” without an actual name or license state.
- Element 6 (medication-specific risks) varies more than you’d expect. Some forms list the boxed warnings explicitly. Others list “common side effects” and call it done.
- Element 9 (right to withdraw) is sometimes present medically but tied to the cancellation and refund policy financially.
7 red flags that should make you pause before clicking “I agree”
These come from the same FDA enforcement actions, NAD advertising decisions, and active 2025–2026 GLP-1 litigation reshaping the legal landscape. Encountering one isn’t automatically disqualifying. Encountering two or three is a real signal to stop and ask.
| # | Red flag | What it usually means | What to do |
|---|---|---|---|
| 1 | "Generic Ozempic," "generic Wegovy," "same active ingredient as Zepbound," or similar phrases implying compounded = FDA-approved | The FDA has flagged this language in warning letters. The drug is not an FDA-approved generic. | Ask in writing: "Is this medication FDA-approved or compounded?" |
| 2 | No clinician name. "Our medical group" or "a licensed provider" without an actual name. | You don't know who is responsible for your care. | Ask: "Who specifically is reviewing my intake, and which state are they licensed in?" |
| 3 | No mention of MTC/MEN 2 contraindications, pregnancy planning, breastfeeding, or reproductive warnings anywhere in the consent. | A required disclosure is missing. | Don't proceed until those are addressed. |
| 4 | Arbitration clause bundled into the same click as medical consent. | These are separate legal agreements that shouldn't be wedged together. | Note the arbitration opt-out window in the Terms of Use and decide separately. |
| 5 | Refund and cancellation tied to whether you withdraw consent. | You're being told that walking away medically costs you money. | Treat these as separate decisions. Stop the medication for medical reasons if needed; handle the refund separately. |
| 6 | No off-label disclosure when the prescription is off-label (e.g., Ozempic for weight loss in a non-diabetic patient). | The patient hasn't been told what they're really getting. | Ask: "Am I being prescribed this drug for its FDA-approved use or off-label?" |
| 7 | The consent form only appears after you've paid. | You can't evaluate the agreement before the financial commitment. | Don't pay until the consent is visible. |
The April 2025 Buchanan Ingersoll & Rooney analysis of the GLP-1 litigation pipeline noted that plaintiffs are casting a wide net — including marketers, influencers, and platform operators — on theories that include not just FDA violations but consumer deception and informed-consent failures.
What to ask before you sign — a copy-paste script
Copy the message below and paste it into your provider’s patient portal or support chat before you click “I agree.” A serious program will answer in plain language.
How to read the answer
| Provider response | What it tells you |
|---|---|
| Clear, specific, in plain language | Good signal. Save the response. Proceed if the answers make sense. |
| Generic marketing copy in reply | Ask again, more specifically. |
| Tells you most of it will be answered after payment or after a clinician visit | The clinician-visit answer is reasonable. The "after payment" answer is not. |
| Refuses to name the medication or pharmacy | Pause. |
| "All GLP-1s are the same" | This is the language FDA has flagged. Pause. |
| Pressures you to pay or inject before answering | Walk away. |
What to do if you already signed
If you signed the consent but haven’t taken your first dose, you still have time. If you’ve already injected, you have a different decision. Both have a path.
If you signed but haven’t taken the first dose yet
- Save the consent. Screenshot the full document, the timestamp, and the URL.
- Save the medication label and shipping records. Photograph the box, vial or pen, lot number, and pharmacy contact info.
- Send the copy-paste script above through the patient portal. Wait for written answers.
- Pause if the medication source, clinician, dose schedule, or urgent-symptom plan are unclear. A delay of a few days to clarify is not a clinical problem for most patients starting a GLP-1.
- Call your primary care doctor if you have a complicated medical history. Tell them what you’ve signed up for.
The medication will still be there next week. The five-minute clarification call is the cheapest insurance you can buy.
If you already took your first dose and are now uncertain
- Read the Medication Guide that came with your shipment, or look up the official FDA Medication Guide on DailyMed.
- Contact the prescribing clinician about any side effects, especially gastrointestinal symptoms or dehydration.
- Seek urgent or emergency care for: severe abdominal pain (especially radiating to the back), signs of allergic reaction (facial or throat swelling, trouble breathing), fainting, severe persistent vomiting, vision changes, or symptoms of dehydration.
- Tell any urgent-care or ER clinician exactly what you took: the drug name, brand or compounded, the dose, the date and time of your last injection.
- Tell your surgeon and anesthesiologist about any GLP-1 use before any planned procedure.
You can stop the medication. You can request your medical records under HIPAA. You can switch providers. The first dose is not a one-way door.
→ Guide: How to share GLP-1 records with your primary care doctor
What “informed consent” doesn’t cover (and what’s bundled with it)
When you click “I agree,” you are usually agreeing to several documents at once. Only one is informed consent. The others affect your money, your data, and your legal rights.
| Document bundled into the same click | What it covers | Why you should read it separately |
|---|---|---|
| Terms of Use | Use of the platform, account, and software | Different from medical consent |
| HIPAA Notice of Privacy Practices | How the provider uses your protected health information | Required by law, but the authorization to share PHI for non-treatment purposes is separate |
| Arbitration clause | Whether you can sue the company in court or must use private arbitration | Read the exact opt-out window and deadline in the provider's current Terms of Use |
| Refund and cancellation policy | What you can get back, when, and under what conditions | Read the exact refund and cancellation deadlines in the provider's current refund policy |
| Auto-renewal and subscription terms | How and when you're charged again | Note the billing cycle and the cancellation deadline |
| Florida Weight-Loss Consumer Bill of Rights (FL residents) | Required separate consumer disclosure for any weight-loss program | A separate document from medical consent |
| California state notices | Specific notices required by Bus. & Prof. Code §2290.5 | Read for your rights as a CA resident |
Frequently asked questions
Is GLP-1 telehealth informed consent required by law?
Telehealth consent requirements vary by state and by type of care. HHS recommends documenting informed consent before telehealth visits, and the majority of states have some telehealth-specific consent requirement, ranging from verbal acknowledgment to written documentation. Florida adds the Weight-Loss Consumer Bill of Rights on top, and California's Telehealth Advancement Act requires that consent be obtained and documented. Expect some form of consent in every state.
What should a GLP-1 telehealth consent form include?
A strong GLP-1 telehealth consent should include nine elements: the clinician's identity and state licensure, your right to refuse telehealth and request in-person care, the limits of telehealth, the named medication and its dose schedule, whether the product is FDA-approved or compounded, the specific medical risks and contraindications, privacy and data-sharing terms, emergency limitations with specific warning symptoms, and your right to withdraw consent at any time.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. They are also not FDA-approved generics of FDA-approved GLP-1 drugs — no FDA-approved generic of semaglutide or tirzepatide exists as of May 2026. A consent form for a compounded GLP-1 should state this in plain language.
Is "generic Ozempic" or "generic Wegovy" a real thing?
No. The FDA has not approved a generic version of semaglutide or tirzepatide. Marketing or consent language that suggests a compounded product is a generic of an FDA-approved drug has been the subject of FDA warning letters in 2024–2026. If you see this phrasing, treat it as a red flag and ask the provider to confirm in writing whether the medication is FDA-approved or compounded.
Can I withdraw GLP-1 telehealth informed consent?
Yes. You can withdraw consent at any time. Withdrawing medical consent and canceling your subscription are separate actions — withdrawing consent does not automatically end billing, and canceling billing does not automatically protect you from a care gap. Handle both. If you've already started the medication, contact the prescriber about how to discontinue safely.
Is a checkbox enough for informed consent?
A checkbox documents that you agreed. It does not, by itself, prove that the underlying conversation happened. State medical boards, FSMB, and AMA all treat informed consent as a process — the form is the record. If the process happened (you saw the disclosures, the clinician was reachable, your questions were answered), the checkbox is fine. If the disclosures were hidden or vague, the checkbox is weak.
Can a GLP-1 be prescribed after only an online questionnaire?
Sometimes. A questionnaire-only intake can be appropriate for some patients and not appropriate for others. The consent should tell you whether the model is asynchronous (questionnaire only), synchronous video, phone, or messaging-based. If you can't tell from the consent whether a real clinician will review your case, ask before you sign.
How do I verify the compounding pharmacy?
Ask for the pharmacy name before payment. Confirm it is a licensed pharmacy through your state's board of pharmacy public license lookup. When the medication arrives, check the label for the pharmacy name, address, lot number, expiration date, concentration, and dose instructions. The FDA has specifically warned against using injectable GLP-1 medication that arrives warm or with insufficient refrigeration — if the package arrives warm, don't inject it.
What if the consent form only appears after I've paid?
That's a structural red flag. You should be able to read what you're agreeing to before you make a financial commitment. If a provider's flow doesn't allow that, you can request the consent in advance via support chat. If they won't share it, the answer to your question is in the refusal.
Should I share my telehealth GLP-1 consent with my primary care doctor?
Yes, especially if you have diabetes, kidney disease, gallbladder history, pancreatitis history, planned pregnancy, complex medications, an upcoming surgery, or any condition where the GLP-1 might interact with your existing care. Your primary care doctor can flag risks the online intake did not.
What we actually verified
We did not use Reddit or forums as evidence for medical or regulatory claims. Primary sources reviewed (verification date: May 16, 2026):
- —FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," April 30, 2026.
- —Federal Register notice, 91 Fed. Reg. 23431 (May 1, 2026). Public comment deadline: June 30, 2026.
- —FDA, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize," April 2026.
- —FDA, "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s," March 3, 2026.
- —FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss."
- —Wegovy and Zepbound prescribing information and Medication Guides, DailyMed.
- —Ozempic, Mounjaro, Saxenda, and Rybelsus prescribing information, DailyMed.
- —Federation of State Medical Boards, "Report of the FSMB Workgroup on Telemedicine," 2022.
- —American Medical Association, Code of Medical Ethics, Opinions 1.1.5 and 1.2.12.
- —HHS Telehealth.gov, "Obtaining Informed Consent."
- —Center for Connected Health Policy, State Telehealth Laws and Reimbursement Policies (current edition).
- —AGA and multi-society guidance on perioperative management of GLP-1 receptor agonists.
- —Florida Statutes §501.0575 and Fla. Admin. Code 64B8-9.012.
- —California Bus. & Prof. Code §2290.5.
- —Mississippi Board of Medical Licensure semaglutide guidance (Aug. 2023) and Supplemental Guidance (Aug. 6, 2024).
- —Public consent pages of five GLP-1 telehealth providers: Ivim Health, Gala GLP-1, Hers (FL-specific), CoraDoc, and Dr. B — verified May 16, 2026.
- —Buchanan Ingersoll & Rooney PC, "GLP-1 Litigation Escalates," April 2025 (industry context only, not primary medical evidence).
Last verified: May 16, 2026.
A note from us
The reason this page exists is that the rest of the first page of search results isn’t really written for you. It’s written for the people who built the consent forms or the regulators who watch them. We made the page that talks to the person staring at the checkbox.
If we did our job, you now know what’s supposed to be there, what’s missing, and what to ask. Use the script. Check the audit. Read your form against the nine elements. If something’s missing, you have permission to slow down.
Related guides
- → GLP-1 Telehealth Safety Checklist: 15-Point Vetting Guide
- → Who Can Prescribe GLP-1 Medications Online (2026)
- → GLP-1 and Oral Contraceptives: Which Birth Control Pills Need Backup?
- → How to Share GLP-1 Records With Your Primary Care Doctor
- → GLP-1 Provider Privacy: 17 Data Questions to Ask
- → Best GLP-1 Telehealth Providers (2026)
- → Find My GLP-1 Path — personalized provider quiz